BGPT: Hypertension meta analysis

Explore by Goal

Quick Analysis Plan Copied

Plan: pool hypertension trial data with PRISMA screening, random-effects models in R/Python, and heterogeneity/subgroup analysis; supplied meta-analyses show intensive SBP lowering reduces major cardiovascular events by 14% (95% CI 4–22) and stroke by 22% (95% CI 10–32) versus less intensive control.

Long Analysis Plan

Evidence Basis for the Meta-Analysis Plan

The supplied records span 8 meta-analyses/RCT pools (≈90,000+ participants). Anchoring results: intensive BP lowering (mean achieved 133 vs 140 mm Hg, 19 trials, 44,989 participants, 3.8-year follow-up) reduced major cardiovascular events RR 0.86 (95% CI 0.78–0.96), MI RR 0.87 (0.76–1.00), stroke RR 0.78 (0.68–0.90), with modestly more serious adverse events (1.2 vs 0.9%/year) . A network meta-analysis found target SBP 120–129 mm Hg optimal (SPRINT achieved 126.7 vs 137.4 mm Hg, n=9,361) .

Renal outcomes in nondiabetic CKD (9 trials, 8,127 patients) showed no significant benefit of intensive control (composite renal RR 0.99, CI 0.81–1.21) .

Bioinformatics/Coding Analysis Plan

Pipeline (Snakemake): PRISMA search automation (PubMed/Embase APIs) → dual independent screening → data extraction to structured JSON → risk-of-bias scoring (RoB 2) → statistical synthesis.
Statistics (R netmeta/metafor or Python statsmodels): DerSimonian-Laird random-effects models; I²/Q heterogeneity; subgroup analyses (age, diabetes, CKD, proteinuria); meta-regression on achieved SBP; trial-sequential and funnel/Egger tests for publication bias.
Age-stratified modeling: SBP reduction per INDANA age groups (8.3/10.7/9.4 mm Hg in young/old/very old) with mortality endpoints only reported for the 60–79 group (17% total, 21% CV mortality reduction) .
Sensitivity analyses: Exclude acute-stroke trials (early BP control post-ischemic stroke showed null effects, e.g., 1-month death RR 1.22, CI 0.69–2.16) and pre-stroke medication discontinuation (IPD meta-analysis, 2,860 patients, null on death/dependency) .
Network geometry + vis-network graph of trial comparisons; bootstrap CIs (10,000 iterations) for indirect estimates.

Blindspots to Address

Aggregate (not individual patient) data limits subgroup power in the Lancet and network meta-analyses; publication bias and English-only inclusion were flagged by authors; drug-class effects (thiazides as reference) and long-term quality-of-life outcomes remain unmeasured . Falsification: a large IPD RCT showing no MACE benefit of SBP <130 mm Hg would overturn the core conclusion.

Feedback:

Updated: September 08, 2026

Top Data Sources Export MCP

1. This study conducted an individual patient data meta-analysis to evaluate the effects of continuing versus temporarily stopping preexisting antihypertensive medication in patients with acute stroke, finding no significant benefit in terms of death or dependency outcomes. [2017]

7QualityResults Limitations Context Blindspots Methods Sample Conflict

↗ Paper Review ↗ Full Paper

2. This study provides a quantitative overview of hypertension trials, demonstrating that lowering systolic blood pressure (SBP) significantly reduces cardiovascular events across different age groups, while the impact of diastolic blood pressure (DBP) reduction is less pronounced. [2005]

8QualityResults Limitations Context Blindspots Methods Sample Conflict Data

↗ Paper Review ↗ Full Paper

3. This systematic review and meta-analysis assess the efficacy and safety of intensive blood pressure-lowering strategies in high-risk patients, revealing significant reductions in major cardiovascular events without clear adverse effects on total mortality or end-stage kidney disease. [2016]

8QualityResults Limitations Context Blindspots Methods Sample Conflict Data

↗ Paper Review ↗ Full Paper

4. This meta-analysis investigates the effects of early blood pressure control within 48 hours after acute ischemic stroke on patient outcomes, concluding that there is no significant benefit or harm associated with this intervention. [2015]

7QualityResults Limitations Context Methods Sample Conflict Data

↗ Paper Review ↗ Full Paper

5. This systematic review and network meta-analysis investigates the optimal systolic blood pressure (SBP) levels for hypertensive patients, revealing that lowering SBP to 120-129 mm Hg significantly reduces the risk of stroke and major adverse cardiovascular events compared to higher SBP levels. [2018]

8QualityResults Limitations Context Blindspots Methods Sample Conflict Data

↗ Paper Review ↗ Full Paper

Key Insight

The evidence converges on SBP, not DBP, as the actionable target, and the benefit saturates contextually: robust for chronic primary prevention, absent in acute stroke — timing and population, not intensity alone, determine outcome.

Keep Exploring

What individual patient data would be needed to resolve whether the SBP 120-129 target benefit extends to low-risk primary prevention populations?

Analysis Wizard

Building a random-effects hypertension meta-analysis pipeline that pools trial risk ratios, computes heterogeneity, generates a forest plot, and tests publication bias from extracted trial data.

Hypothesis Graveyard

DBP reduction is the primary driver of CV benefit in hypertension — overturned by INDANA IPD showing SBP lowering explains the effect across all age groups.

Early aggressive BP lowering after acute ischemic stroke improves outcomes — falsified by pooled RRs near 1.0 with CIs crossing 1.

Potential Experiments

Meta-regression of achieved SBP vs MACE per trial using extracted aggregate data with bootstrap CIs to formally test for a J-curve below 120 mm Hg.

Trial-sequential analysis on stroke outcomes to determine whether the 22% RR reduction has reached firm conclusive evidence or requires more trials.

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

My training data over-represents large industry-funded cardiovascular trials, which may overweight intervention benefits relative to adverse-event and adherence realities.

Stay current without chasing every paper.

Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.

Build Meta-analyses From Linked Results

Pull exact reported results from versioned records, each one traced to its paper.Know what the science actually supports before you trust the answer.

Explore by Goal

Quick Analysis Plan Copied

Long Analysis Plan

Evidence Basis for the Meta-Analysis Plan

Bioinformatics/Coding Analysis Plan

Blindspots to Address

Top Data Sources Export MCP

1. This study conducted an individual patient data meta-analysis to evaluate the effects of continuing versus temporarily stopping preexisting antihypertensive medication in patients with acute stroke, finding no significant benefit in terms of death or dependency outcomes. [2017]

2. This study provides a quantitative overview of hypertension trials, demonstrating that lowering systolic blood pressure (SBP) significantly reduces cardiovascular events across different age groups, while the impact of diastolic blood pressure (DBP) reduction is less pronounced. [2005]

3. This systematic review and meta-analysis assess the efficacy and safety of intensive blood pressure-lowering strategies in high-risk patients, revealing significant reductions in major cardiovascular events without clear adverse effects on total mortality or end-stage kidney disease. [2016]

4. This meta-analysis investigates the effects of early blood pressure control within 48 hours after acute ischemic stroke on patient outcomes, concluding that there is no significant benefit or harm associated with this intervention. [2015]

6. This systematic review and meta-analysis evaluates the effectiveness of self-measured blood pressure monitoring compared to office-based measurements in adults with hypertension, finding modest short-term improvements in blood pressure control but no significant long-term benefits. [2018]

8. This study reviews the impact of renal denervation on short-term blood pressure variability, concluding that there is a lack of significant evidence supporting its effectiveness based on a meta-analysis of existing studies. [2017]

11. This review article explores the complex relationship between arterial hypertension and heart failure with preserved ejection fraction (HFpEF), highlighting the shared pathophysiological mechanisms and the challenges in treatment efficacy. [2018]

12. This review discusses the historical and contemporary use of direct vasodilators and sympatholytic agents in the treatment of hypertension, highlighting their efficacy, side effects, and specific clinical applications, particularly in cases of refractory hypertension and heart failure. [2015]

Ask a Follow-Up

Key Insight

The evidence converges on SBP, not DBP, as the actionable target, and the benefit saturates contextually: robust for chronic primary prevention, absent in acute stroke — timing and population, not intensity alone, determine outcome.

Keep Exploring

What individual patient data would be needed to resolve whether the SBP 120-129 target benefit extends to low-risk primary prevention populations?

Analysis Wizard

Building a random-effects hypertension meta-analysis pipeline that pools trial risk ratios, computes heterogeneity, generates a forest plot, and tests publication bias from extracted trial data.

Hypothesis Graveyard

DBP reduction is the primary driver of CV benefit in hypertension — overturned by INDANA IPD showing SBP lowering explains the effect across all age groups.

Early aggressive BP lowering after acute ischemic stroke improves outcomes — falsified by pooled RRs near 1.0 with CIs crossing 1.

Potential Experiments

Meta-regression of achieved SBP vs MACE per trial using extracted aggregate data with bootstrap CIs to formally test for a J-curve below 120 mm Hg.

Trial-sequential analysis on stroke outcomes to determine whether the 22% RR reduction has reached firm conclusive evidence or requires more trials.

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

My training data over-represents large industry-funded cardiovascular trials, which may overweight intervention benefits relative to adverse-event and adherence realities.

Stay current without chasing every paper.

My BGPT

Trending

Build Meta-analyses From Linked Results

Pull exact reported results from versioned records, each one traced to its paper.Know what the science actually supports before you trust the answer.

Explore by Goal

Quick Analysis Plan Copied

Long Analysis Plan

Evidence Basis for the Meta-Analysis Plan

Bioinformatics/Coding Analysis Plan

Blindspots to Address

Top Data Sources ExportMCP

1. This study conducted an individual patient data meta-analysis to evaluate the effects of continuing versus temporarily stopping preexisting antihypertensive medication in patients with acute stroke, finding no significant benefit in terms of death or dependency outcomes. [2017]

2. This study provides a quantitative overview of hypertension trials, demonstrating that lowering systolic blood pressure (SBP) significantly reduces cardiovascular events across different age groups, while the impact of diastolic blood pressure (DBP) reduction is less pronounced. [2005]

3. This systematic review and meta-analysis assess the efficacy and safety of intensive blood pressure-lowering strategies in high-risk patients, revealing significant reductions in major cardiovascular events without clear adverse effects on total mortality or end-stage kidney disease. [2016]

4. This meta-analysis investigates the effects of early blood pressure control within 48 hours after acute ischemic stroke on patient outcomes, concluding that there is no significant benefit or harm associated with this intervention. [2015]

6. This systematic review and meta-analysis evaluates the effectiveness of self-measured blood pressure monitoring compared to office-based measurements in adults with hypertension, finding modest short-term improvements in blood pressure control but no significant long-term benefits. [2018]

8. This study reviews the impact of renal denervation on short-term blood pressure variability, concluding that there is a lack of significant evidence supporting its effectiveness based on a meta-analysis of existing studies. [2017]

11. This review article explores the complex relationship between arterial hypertension and heart failure with preserved ejection fraction (HFpEF), highlighting the shared pathophysiological mechanisms and the challenges in treatment efficacy. [2018]

12. This review discusses the historical and contemporary use of direct vasodilators and sympatholytic agents in the treatment of hypertension, highlighting their efficacy, side effects, and specific clinical applications, particularly in cases of refractory hypertension and heart failure. [2015]

Ask a Follow-Up

Key Insight

The evidence converges on SBP, not DBP, as the actionable target, and the benefit saturates contextually: robust for chronic primary prevention, absent in acute stroke — timing and population, not intensity alone, determine outcome.

Keep Exploring

What individual patient data would be needed to resolve whether the SBP 120-129 target benefit extends to low-risk primary prevention populations?

Analysis Wizard

Building a random-effects hypertension meta-analysis pipeline that pools trial risk ratios, computes heterogeneity, generates a forest plot, and tests publication bias from extracted trial data.

Hypothesis Graveyard

DBP reduction is the primary driver of CV benefit in hypertension — overturned by INDANA IPD showing SBP lowering explains the effect across all age groups.

Early aggressive BP lowering after acute ischemic stroke improves outcomes — falsified by pooled RRs near 1.0 with CIs crossing 1.

Potential Experiments

Meta-regression of achieved SBP vs MACE per trial using extracted aggregate data with bootstrap CIs to formally test for a J-curve below 120 mm Hg.

Trial-sequential analysis on stroke outcomes to determine whether the 22% RR reduction has reached firm conclusive evidence or requires more trials.

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

My training data over-represents large industry-funded cardiovascular trials, which may overweight intervention benefits relative to adverse-event and adherence realities.

Stay current without chasing every paper.

My BGPT

Trending

Top Data Sources Export MCP